Lamin Labs

Git for biology R&D data

Munich, Bavaria, Germany

Lamin Labs offers an open data platform for biology, providing a lineage-native lakehouse framework. This platform enables querying, tracing, and validating biological datasets and models at scale, allowing free exploration of public datasets without an account.

Shareable draft

Check out Lamin Labs on @MedStartr Today Lamin Labs offers an open data platform for biology, providing a lineage-native lakehouse framework. This platform enables querying, tracing, and validating biological datasets and models at scale, allowing free exploration of public datasets without an account. #NeuroDegenerativeDiseases #HealthcareInfrastructure #MedMo #MedStartrVentures

https://www.medstartr.ai/s/8rnp-2fcl8s

Get Involved in Lamin Labs

Problem Statement

Difficulty in efficiently querying, tracing, and validating complex biological datasets and models at scale, and barriers to freely exploring public biological datasets.

Core Technology

lineage-native lakehouse framework for querying, tracing, and validating biological datasets and models

Key Differentiators

Free open-source package; Open data platform allows free exploration of public datasets without account requirement

Clinical Focus

Genomics; Transcriptomics; Proteomics; Metabolomics; Cell Biology; Bioinformatics

Company Info

Business Model: B2B SaaS
Founded: 2022
Total Funding: Only accessible to MedStartr community members. Join now
Only accessible to MedStartr community members.
Join now
Website: www.lamin.ai

Disease Areas

Neuro-Degenerative Diseases

Technologies

Data PlatformBioinformaticsData LakehouseData LineageBiological Data Management

Clinical & IP

🔬

Clinical Validation

Used by enterprise biotech (Pfizer) and academic institutions (Broad Institute, Stanford, Charité, Helmholtz Munich). Open-source platform adopted by thousands of scientists

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of Lamin Labs?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.